EP1855650B1 - Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation - Google Patents

Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation Download PDF

Info

Publication number
EP1855650B1
EP1855650B1 EP06707447A EP06707447A EP1855650B1 EP 1855650 B1 EP1855650 B1 EP 1855650B1 EP 06707447 A EP06707447 A EP 06707447A EP 06707447 A EP06707447 A EP 06707447A EP 1855650 B1 EP1855650 B1 EP 1855650B1
Authority
EP
European Patent Office
Prior art keywords
metronidazole
solution
medium
water
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06707447A
Other languages
German (de)
English (en)
Other versions
EP1855650A1 (fr
Inventor
Leila Zarif
Gérald PEDRASSI
Alain Brzokewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Priority to PL06707447T priority Critical patent/PL1855650T3/pl
Priority to SI200631537T priority patent/SI1855650T1/sl
Publication of EP1855650A1 publication Critical patent/EP1855650A1/fr
Application granted granted Critical
Publication of EP1855650B1 publication Critical patent/EP1855650B1/fr
Priority to CY20131100208T priority patent/CY1113783T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Definitions

  • the present invention relates to a novel method for preparing metronidazole-based aqueous gels which are useful in particular as topical dermatological compositions, especially for the treatment of dermatoses, such as rosacea.
  • Metronidazole or 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole, is the compound of the formula (I) :
  • Metronidazole is an acknowledged antibacterial and antiparasitic agent useful for the treatment of many conditions. This compound is known in particular as being particularly effective in the treatment of skin disorders such as rosacea.
  • Rosacea is a chronic skin condition which affects mainly adults. It is a type of dermatosis with recurrent symptoms, including in particular erythemas, papules, pustules, rhinophymas and/or telangiectasias, which manifests itself mainly in the region of the nose, the cheeks and the forehead.
  • metronidazole is preferably administered by the topical route.
  • administration by the systemic route in particular by the oral route, leads, in most cases, to undesirable side effects, such as gastrointestinal intolerance or vaginitis, to which other chronic disorders may also be added in the case of a long-term administration.
  • metronidazole which are mainly oil-based compositions, in particular creams (oil-in-water emulsions) or ointments (in particular compositions based on petroleum jelly).
  • metronidazole is dissolved in the oily phase.
  • oil-based compositions have the advantage of being able to contain large quantities of metronidazole in the solubilised state, available for topical application.
  • they are found, in practice, to be poorly suited to dermatological use. Indeed, they require the presence of ingredients, in particular oils, emulsifiers or surfactants, which are found to exhibit comedogenic, acneigenic, drying and/or irritating properties for the skin.
  • patients treated with compositions of this type often feel sensations of burning or urtication.
  • compositions in the form of aqueous gels which do not require the presence of comedogenic, acneigenic, drying and/or irritating agents present in the abovementioned oil-based compositions.
  • compositions of US 4,837,378 comprise metronidazole in an aqueous phase gelled with a polymeric gelling agent, such as a polycarboxylated vinyl polymer.
  • a polymeric gelling agent such as a polycarboxylated vinyl polymer.
  • compositions of US 4,837,378 may additionally comprise additional agents, such as propylene glycol which improve the efficacy of administration of metronidazole, or preservatives such as methylparaben or propylparaben. Where appropriate, these additives are added to the preformed solution of metronidazole in water, and then the mixture obtained is mixed with the gelling polymer.
  • additional agents such as propylene glycol which improve the efficacy of administration of metronidazole, or preservatives such as methylparaben or propylparaben.
  • aqueous gels of US 4,837,378 have numerous advantages, in addition to the fact that they do not comprise ingredients capable of leading to the side effects observed with the abovementioned oil-based compositions. In particular, they allow better control of application and a uniform distribution of the active ingredient. Furthermore, they act as prolonged-release systems, which gradually deliver the active ingredient topically, in a therapeutically effective amount for a prolonged period.
  • One aim of the present invention is to provide aqueous gels for the topical administration of metronidazole having the advantages of the compositions of US 4,837,378 , but additionally having increased stability over time.
  • the expression "stability" of an aqueous metronidazole gel is understood to mean its capacity to retain its gel structure over a long period, with metronidazole mainly in the dissolved and non-crystallized state. It is considered that a gel is all the more stable if the period during which is retains its gel structure with metronidazole mainly in the dissolved state is long.
  • the subject of the present invention is a method for preparing a stable aqueous gel based on metronidazole, comprising the successive steps consisting in:
  • metronidazole-based aqueous gel is understood to mean a gelled aqueous phase, preferably monophasic, and containing metronidazole.
  • this gel contains metronidazole as sole active ingredient with a cosmetic or pharmaceutical effect.
  • the metronidazole is present in the gel in a therapeutically effective quantity.
  • This metronidazole content may vary according to the application envisaged for the gel, but it advantageously remains between 0.25% and 1.0% by mass, and it is typically of the order of 0.75 to 0.8% by mass relative to the total mass of the aqueous gel.
  • the inventors have demonstrated that, during the preparation of such an aqueous gel, a dissolution of the metronidazole in a medium initially containing water and propylene glycol, of the M medium type in step (B), makes it possible to obtain aqueous metronidazole gels having high stability.
  • the work by the inventors has in particular made it possible to establish that the use of this specific step of dissolution in a propylene glycol-based medium makes it possible to obtain gels with increased stability compared to the gels obtained according to the methods of US 4,837,378 , where the metronidazole is first dissolved in water, and where propylene glycol is introduced into the medium afterwards.
  • the method of the invention requires in general much less propylene glycol than the method of US 4,837,378 , where this compound is introduced in an amount of 7.9% by mass into the metronidazole dispersion.
  • This use of propylene glycol in a limited quantity constitutes another advantage of the method of the invention, in particular from an economic point of view.
  • the stabilizing effect observed by the inventors is at least partly due to the fact that a mixture of water and propylene glycol allows a very good solubilization of metronidazole, in particular when the water and the propylene glycol are present in the abovementioned advantageous ranges, whereas a lower solubilization is obtained when the propylene glycol is introduced after the dissolution of the metronidazole in water, even when the propylene glycol is post-introduced in large quantities as in the method of US 4,837,378 .
  • the inventors have demonstrated that while metronidazole has a solubility in water of the order of 0.78%, water/propylene glycol mixtures can bring about higher solubilities.
  • medium M formed in step (A) comprises a preservative in addition to the water and the propylene glycol, this preservative being preferably present in a quantity effective to inhibit microbial growth in the gel during its storage.
  • this preservative is chosen from the paraben family.
  • a mixture of methylparaben and of propylparaben is found to be particularly advantageous to this effect.
  • the presence of preservatives such as parabens in medium M also makes it possible, in some cases, to improve the solubilization of metronidazole during step (B), and it also leads to an improvement in the stability of the gel obtained.
  • Medium M most often consists of a mixture of water, propylene glycol and optionally preservatives of the abovementioned type, excluding any other compound. Nevertheless, the presence of other chemical species is not excluded insofar as they do not hamper effective solubilization of metronidazole in step (B).
  • the medium of step (A) may for example comprise ethylene diamine tetraacetic acid (EDTA) or one of its salts as additional ingredient, although it is most often preferable for this acid to be introduced after the dissolution of metronidazole in step (B).
  • EDTA ethylene diamine tetraacetic acid
  • EDTA which is commonly used in dermatological compositions, is useful in particular for chelating metal cations which may be present as impurities in the composition, which makes it possible in particular to avoid undesirable side effects in some patients.
  • EDTA also inhibits the phenomena of browning of the composition which can occur during storage of the gel, in particular when the pH of the gel is of the order of 3.5 to 5.4.
  • the gel prepared according to the method of the present invention advantageously contains EDTA, preferably in an amount of 0.01 to 0.1% by mass, and typically in an amount of the order of 0.05% by mass.
  • step (B) the dissolution of metronidazole in this medium M is carried out at a temperature greater than 40°C, this temperature being advantageously at least 45°C, and most preferably at least 50°C, in particular in order to obtain optimum dissolution of the metronidazole. It is preferable, moreover, that this temperature remains less than 70°C, and preferably less than or equal to 60°C, in particular for economic reasons. Thus, this temperature is typically of the order of 50 to 55°C.
  • step (B) the metronidazole is introduced into medium M with a mass ratio (metronidazole/medium M) which is most often between 0.5 and 2.5, for example between 0.8 and 2.2, typically between 1 and 2.
  • step (B) simply consists in dissolving metronidazole in medium M prepared in step (A).
  • step (B) consists in dissolving, in a first instance, the metronidazole in medium M prepared in step (A), and then in diluting the metronidazole solution by adding water.
  • the water is in general introduced alone as dilution medium, but it is not impossible, according to a particular embodiment, for the water for dilution to be introduced in the form of an aqueous solution containing water-soluble compounds, for example EDTA.
  • this step leads to a solution S of metronidazole in aqueous medium being obtained.
  • This solution S has, in general, a metronidazole concentration greater than 0.5% by mass, and it is typically between 0.7 and 2.5% by mass, relative to the total mass of solution S.
  • the metronidazole is mainly in solubilized form.
  • less than 1%, and most often less than 0.5%, or even less than 0.1%, of the total mass of metronidazole is in the insolubilized state.
  • Step (C) of mixing solution S with the gelling polymer may be carried out by any means known to persons skilled in the art.
  • the gelling agent may in particular be simply introduced into solution S.
  • the polymer may first be mixed with water, and optionally with other water-soluble compounds such as EDTA or pH-regulating agents such as sodium hydroxide, to form a pre-gel, this pre-gel then being mixed with solution S.
  • the gelling polymer used in step (C) may be any polymer suitable for gelling an aqueous phase in order to form a gel of uniform structure.
  • This is preferably a water-dispersible polymer, having high affinity for water, this polymer being preferably a polymer having free carboxyl groups which are completely or partly neutralizable in the form of carboxylates with a base.
  • Particularly advantageous gelling polymers in step (C) are vinyl polymers with water-dispersible carboxylate groups, in particular poly(acrylic acids) neutralized with a base.
  • Most particularly advantageous are polymers having a molecular mass of the order of 1 250 000 to 4 000 000.
  • suitable poly(acrylic acids) are for example the poly(acrylic acids) crosslinked with compounds of the polyalkenyl polyether type, such as carbomers, such as the polymers available from the company Goodrich under the trade name Carbopol 934, 940 or 941, Carbopol 940 being most particularly preferred.
  • carbomers such as the polymers available from the company Goodrich under the trade name Carbopol 934, 940 or 941, Carbopol 940 being most particularly preferred.
  • the neutralization of the carboxyl groups in the gelling polymers described above may be carried out by adding to the gel a base, for example aqueous ammonia, NaOH or organic amines, such as alkylamines (for example methylamine, ethylamine) or alternatively dialkylamines, trialkylamines, alkanolamines or dialkanolamines.
  • a base for example aqueous ammonia, NaOH or organic amines, such as alkylamines (for example methylamine, ethylamine) or alternatively dialkylamines, trialkylamines, alkanolamines or dialkanolamines.
  • alkylamines for example methylamine, ethylamine
  • dialkylamines trialkylamines
  • alkanolamines or dialkanolamines alkanolamines
  • the final pH of the gel may vary widely according to the application envisaged. However, most often, this pH is of the order of 3
  • the gelling polymer is introduced in step (C) in a sufficient quantity to lead in fine to a gel being obtained.
  • this quantity is sufficient to produce a viscosity suitable for topical application of the gel, in particular for dermatological applications.
  • the gelling polymer is advantageously introduced in step (C) in a quantity such that its final content in the gel is between 0.2% and 7.0% by mass, preferably between 0.5% and 1.5% by mass, relative to the total mass of the gel, this content being typically of the order of 0.6% by mass.
  • steps (A) to (B) of the method of the invention consist in:
  • steps (A1) to (C1) advantageously consist in:
  • steps (A2) to (C2) of the method of the invention consist in:
  • steps (A2) to (C2) consist in:
  • the method of the invention makes it possible to obtain metronidazole-based aqueous gels which have a high stability during their storage.
  • These particularly stable compositions constitute a second subject of the present invention.
  • compositions in particular aqueous gels, which can be obtained according to one of the methods described above.
  • compositions are in particular suitable for the preparation of a medicament intended for application by the topical route for the prophylactic or therapeutic treatment of skin conditions, in particular in human beings.
  • these compositions are in particular suitable for the treatment of rosacea, or of various forms of acne, such as acne vulgaris, acne conglobata or nodulocystic acne, or certain types of dermatitis, such as perioral or seborrhoeic dermatitis.
  • Example 1 Method for preparing an aqueous gel G1 based on metronidazole
  • aqueous gel G1 based on metronidazole was prepared under the following conditions:
  • a homogeneous solvent medium based on water and propylene glycol was thus obtained.
  • the solution (s1) obtained was gelled by adding 6.5 kg of Carbomer 940 (marketed by Goodrich), in a dry form.
  • the gelling agent was introduced gradually, with stirring with the aid of a scraper at 25 revolutions per minute and a turbine at 3000 revolutions per minute, for 30 minutes.
  • Example 2 Method for preparing an aqueous gel G2 based on metronidazole
  • aqueous gel G2 based on metronidazole was prepared under the following conditions:
  • a mixture of 1.04 kg of methylparaben and 0.26 kg of propylparaben was gradually added to 36 kg of propylene glycol, with stirring. The stirring was maintained until complete dissolution of the methylparaben and propylparaben had been obtained.
  • the medium thus obtained was introduced into 429 litres of purified water, kept stirred in a 700 litre jacketed reactor, at a temperature of between 50 and 55°C. The mixing was carried out with the aid of a dispersing device.
  • a homogeneous solvent medium based on water and propylene glycol was thus obtained.
  • a solution of 1.3 kg of NaOH in 13 litres of water was then introduced into the medium.
  • the medium was then subjected to stirring at 30 revolutions per minute for 90 minutes.
  • This gelled phase was mixed with the solution (s2) of metronidazole obtained above, at 55°C.
  • the mixture was prepared by introducing the solution (s1) into the gelled aqueous phase, allowing the medium to cool to 33°C, and then mixing with coaxial stirring at 30 revolutions per minute for 120 minutes.
  • Example 3 Method for preparing an aqueous gel G3 based on metronidazole
  • aqueous gel based on metronidazole was prepared under the following conditions:
  • the mixture thus obtained was introduced into 660 litres of purified water, kept stirred at 1000 revolutions per minute in a reactor kept at a temperature of 53°C +/- 2°C.
  • a homogeneous solvent medium based on water and propylene glycol was thus obtained.
  • a solution of 2 kg of NaOH in 20 litres of purified water was then introduced into the medium.
  • the medium was then subjected to stirring at 1000 revolutions per minute, under a -0.6b vacuum, for 90 minutes.
  • the solution (s1) of metronidazole prepared above was mixed with this gelled phase.
  • the mixture was prepared by introducing the solution (s3) prepared above into the gelled aqueous phase, allowing the medium to cool to 31°C +/- 2°C, and then mixing, with coaxial stirring at 30 revolutions per minute under a -0.8b vacuum, for 120 minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Claims (11)

  1. Procédé de préparation d'un gel aqueux stable à base de métronidazole, comprenant les étapes successives consistant à :
    (A) former un milieu solvant M comprenant de l'eau et du propylène glycol ;
    (B) dissoudre le métronidazole dans ce milieu solvant M, cette dissolution étant éventuellement suivie par une dilution du milieu obtenu par addition d'eau, ce par quoi on obtient une solution S de métronidazole ; puis
    (C) mélanger la solution S obtenue avec un polymère gélifiant ayant des groupements carboxyliques libres qui sont entièrement ou partiellement neutralisables sous forme de carboxylates, en une quantité suffisante pour assurer la gélification de la composition.
  2. Procédé selon la revendication 1, où le rapport massique propylène glycol/eau dans le milieu M formé dans l'étape (A) est compris entre 2% et 15%.
  3. Procédé selon la revendication 1 ou selon la revendication 2, où le milieu .M formé dans l'étape (A) contient en outre un agent conservateur.
  4. Procédé selon la revendication 3, où l'agent conservateur est un mélange de méthylparabène et de propylparabène.
  5. Procédé selon l'une quelconque des revendications précédentes, où, dans l'étape (B), la dissolution du métronidazole dans le milieu M est réalisée à une température comprise entre 40 et 60°C.
  6. Procédé selon l'une quelconque des revendications précédentes, où, dans l'étape (B), le métronidazole est introduit dans le milieu M avec un rapport massique (métrodinazole/milieu M) compris entre 0,5 et 2,5 %.
  7. Procédé selon la revendication 6, dans laquelle la solution de métronidazole S obtenue à l'issue de l'étape (B) a une concentration en métronidazole supérieure à 0,5 % en masse, par rapport à la masse totale de la solution aqueuse.
  8. Procédé selon l'une quelconque des revendications précédentes, où, dans la solution de métronidazole S obtenue à l'issue de l'étape (B), moins de 1% de la masse totale du métronidazole est à l'état insolubilisé.
  9. Procédé selon la revendication 1, comprenant les étapes consistant à :
    (a1) former un milieu M comprenant de 96% à 98% d'eau, de 2% à 5% de propylène glycol, de 0 à 2% d'agents conservateurs, et de 0 à 2% d'EDTA ;
    (b1) dissoudre du métronidazole dans le milieu aqueux M ainsi formé, avec un rapport massique métronidazole/milieu M compris entre 0,5% et 1%, de façon à former une solution S de métronidazole ; puis (c1) introduire dans la solution S obtenue un polymère gélifiant porteur de groupements carboxyliques libres neutralisés sous forme de carboxylates, avec un rapport massique polymère gélifiant/solution S compris entre 0,5% et 1%.
  10. Procédé selon l'une quelconque des revendications 1 à 9, comprenant les étapes consistant à :
    (A2) former un milieu M comprenant de l'eau et du propylène glycol ;
    (B2) dissoudre le métronidazole dans le milieu aqueux M ainsi formé, de façon à former une solution S' de métronidazole, puis ajouter de l'eau à cette solution S', ce par quoi on obtient une solution S de métronidazole ; puis
    (C2) mélanger la solution S obtenue à une phase aqueuse gélifiée contenant un polymère gélifiant porteur de groupements carboxyliques libres neutralisés sous forme de carboxylates, en une quantité suffisante pour assurer la gélification de la totalité de la composition.
  11. Procédé selon ta revendication 10, comprenant les étapes consistant à :
    (a2) former un milieu M comprenant 90% à 95% d'eau, 5% à 10% de propylène glycol, et de 0 à 0,5% d'agents conservateurs ;
    (b2) dissoudre du métronidazole dans le milieu aqueux M ainsi formé, avec un rapport massique métronidazole/milieu M compris entre 1,5% et 2,5% de façon à former une solution S' de métronidazole, puis ajouter de l'eau à cette solution S' de façon à obtenir une solution S de métronidazole ayant une teneur en métronidazole de 1% à 2,2% ; puis
    (c2) mélanger la solution S obtenue à une phase aqueuse gélifiée contenant 98% à 99,5% d'eau, 0,5% à 1,5% d'un polymère gélifiant porteur de groupements carboxyliques libres neutralisés sous forme de carboxylates, avec un rapport massique phase aqueuse gélifiante/solution S compris entre 1,4 1 et 1,8 : 1.
EP06707447A 2005-02-25 2006-02-16 Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation Active EP1855650B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL06707447T PL1855650T3 (pl) 2005-02-25 2006-02-16 Wodny miejscowy żel o wysokiej stabilności, oparty na metronidazolu, i sposób otrzymywania
SI200631537T SI1855650T1 (sl) 2005-02-25 2006-02-16 Vodni topikalni gel z visoko stabilnostjo na osnovi metronidazola in postopek priprave
CY20131100208T CY1113783T1 (el) 2005-02-25 2013-03-05 Υδατικη τοπικη γελη υψηλης σταθεροτητας με βαση την μετρονιδαζολη και μεθοδος παρασκευης

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0501949A FR2882552B1 (fr) 2005-02-25 2005-02-25 Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation
US67163505P 2005-04-15 2005-04-15
PCT/EP2006/002074 WO2006089804A1 (fr) 2005-02-25 2006-02-16 Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation

Publications (2)

Publication Number Publication Date
EP1855650A1 EP1855650A1 (fr) 2007-11-21
EP1855650B1 true EP1855650B1 (fr) 2012-12-05

Family

ID=35044713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06707447A Active EP1855650B1 (fr) 2005-02-25 2006-02-16 Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation

Country Status (19)

Country Link
US (1) US20090215849A1 (fr)
EP (1) EP1855650B1 (fr)
JP (1) JP2008531517A (fr)
KR (1) KR20070112139A (fr)
CN (1) CN101128185A (fr)
AR (1) AR054228A1 (fr)
AU (1) AU2006218043B2 (fr)
BR (1) BRPI0608044A2 (fr)
CA (1) CA2598031A1 (fr)
DK (1) DK1855650T3 (fr)
ES (1) ES2400502T3 (fr)
FR (1) FR2882552B1 (fr)
MX (1) MX2007010179A (fr)
PL (1) PL1855650T3 (fr)
PT (1) PT1855650E (fr)
RU (1) RU2409346C2 (fr)
SI (1) SI1855650T1 (fr)
WO (1) WO2006089804A1 (fr)
ZA (1) ZA200707558B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103763925A (zh) 2011-06-28 2014-04-30 梅迪奇制药有限公司 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途
CN113476397B (zh) * 2021-07-12 2022-11-18 海南海神同洲制药有限公司 一种甲硝唑凝胶及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
JPH0825878B2 (ja) * 1987-03-20 1996-03-13 ガルデルマ エスアー 局所的メトロニダゾール製剤
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
JP2533723B2 (ja) * 1992-12-28 1996-09-11 東興薬品工業株式会社 速乾性ゲルタイプ手指消毒剤
FR2700952B1 (fr) * 1993-01-29 1995-03-17 Oreal Nouvelles compositions cosmétiques ou dermopharmaceutiques sous forme de gels aqueux modifiés par addition de microsphères expansées.
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
IN188720B (fr) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
EP1071413B1 (fr) * 1998-04-17 2004-06-16 Bertek Pharmaceuticals, Inc. Formulations topiques destinees au traitement des mycoses ungueales
US7074832B2 (en) * 2001-09-24 2006-07-11 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US7368122B1 (en) * 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
PE20040321A1 (es) * 2002-08-22 2004-07-15 Novartis Consumer Health Sa Composicion topica que comprende diclofenaco
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions

Also Published As

Publication number Publication date
ES2400502T3 (es) 2013-04-10
EP1855650A1 (fr) 2007-11-21
CA2598031A1 (fr) 2006-08-31
ZA200707558B (en) 2008-10-29
FR2882552A1 (fr) 2006-09-01
BRPI0608044A2 (pt) 2009-11-03
RU2007135364A (ru) 2009-03-27
PL1855650T3 (pl) 2013-04-30
WO2006089804A1 (fr) 2006-08-31
MX2007010179A (es) 2007-09-18
CN101128185A (zh) 2008-02-20
AU2006218043A1 (en) 2006-08-31
AR054228A1 (es) 2007-06-13
FR2882552B1 (fr) 2008-12-26
DK1855650T3 (da) 2013-02-25
US20090215849A1 (en) 2009-08-27
JP2008531517A (ja) 2008-08-14
PT1855650E (pt) 2013-02-28
AU2006218043B2 (en) 2012-02-02
KR20070112139A (ko) 2007-11-22
SI1855650T1 (sl) 2013-05-31
RU2409346C2 (ru) 2011-01-20

Similar Documents

Publication Publication Date Title
JP5526035B2 (ja) アダパレンゲルの製造方法
WO2019014380A1 (fr) Plates-formes pour administration topique de médicaments et leurs procédés de préparation
US11534493B2 (en) Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
IE850146L (en) Topical drug release system
JPH0338250B2 (fr)
KR950003919B1 (ko) 국소용 메트로니다졸 제제의 제조방법
WO2010047831A1 (fr) Formulations de gel de métronidazole stables
US8563535B2 (en) Combination composition comprising benzoyl peroxide and adapalene
EP3097907B1 (fr) Formulation de gel comprenant des agents analgésiques et anesthésiants
CA2429205C (fr) Formulations dermatologiques
EP1855650B1 (fr) Gel topique aqueux a stabilite elevee, a base de metronidazole, et procede de preparation
EP3709968B1 (fr) Émulsions destinés au traitement d'infections vaginales
US20100004338A1 (en) Topical gel composition comprising azelaic acid
WO2016149376A1 (fr) Traitement de l'acné vulgaire au moyen de formulations topiques séquentielles comprenant des anions d'acides organiques antimicrobiens en phase alcaline
JP2005527561A (ja) 小動物用の注射可能な獣医用組成物
WO2016137411A1 (fr) Composition de spray topique comprenant de l'ibuprofène et de la lidocaïne
JPWO2010109544A1 (ja) 核酸を有効成分とする外用剤組成物
EP2340016B1 (fr) Formule topique de dihydrate propionate 3-(2,2,2-trimethylhydrazinium)
JPS63287721A (ja) 消炎鎮痛ゲル剤
JP2006117539A (ja) 油性軟膏剤
JPH11199484A (ja) 外用剤組成物
WO2022003168A1 (fr) Formulation de gel topique contenant de l'asimadoline
JP2014156481A (ja) 核酸を有効成分とする外用剤組成物
JP2005008569A (ja) ジフルプレドナート製剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20071213

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PEDRASSI, GERALD,RESIDENCE LES GRANDES FUTAIES

Inventor name: ZARIF, LEILA

Inventor name: BRZOKEWICZ, ALAIN

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PEDRASSI, GERALD

Inventor name: ZARIF, LEILA

Inventor name: BRZOKEWICZ, ALAIN

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BRZOKEWICZ, ALAIN

Inventor name: ZARIF, LEILA

Inventor name: PEDRASSI, GERALD

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 586872

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006033448

Country of ref document: DE

Effective date: 20130131

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20130219

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2400502

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130410

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E007504

Country of ref document: EE

Effective date: 20130226

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20130400466

Country of ref document: GR

Effective date: 20130418

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130906

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 14884

Country of ref document: SK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E017811

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006033448

Country of ref document: DE

Effective date: 20130906

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20141212

Year of fee payment: 10

Ref country code: MC

Payment date: 20141219

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20150210

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20150209

Year of fee payment: 10

Ref country code: CZ

Payment date: 20150205

Year of fee payment: 10

Ref country code: PT

Payment date: 20150216

Year of fee payment: 10

Ref country code: DK

Payment date: 20150210

Year of fee payment: 10

Ref country code: EE

Payment date: 20150203

Year of fee payment: 10

Ref country code: IE

Payment date: 20150210

Year of fee payment: 10

Ref country code: SK

Payment date: 20150119

Year of fee payment: 10

Ref country code: HU

Payment date: 20150115

Year of fee payment: 10

Ref country code: LU

Payment date: 20150204

Year of fee payment: 10

Ref country code: IS

Payment date: 20150106

Year of fee payment: 10

Ref country code: LT

Payment date: 20150122

Year of fee payment: 10

Ref country code: RO

Payment date: 20150114

Year of fee payment: 10

Ref country code: CH

Payment date: 20150213

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20150120

Year of fee payment: 10

Ref country code: SE

Payment date: 20150212

Year of fee payment: 10

Ref country code: AT

Payment date: 20150126

Year of fee payment: 10

Ref country code: GR

Payment date: 20150114

Year of fee payment: 10

Ref country code: TR

Payment date: 20150213

Year of fee payment: 10

Ref country code: LV

Payment date: 20150202

Year of fee payment: 10

Ref country code: PL

Payment date: 20150210

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20150211

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20150202

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20160216

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E007504

Country of ref document: EE

Effective date: 20160229

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20160229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 586872

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160831

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160217

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 14884

Country of ref document: SK

Effective date: 20160216

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20160301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160217

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160816

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160217

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160905

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20161013

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160301

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20130400466

Country of ref document: GR

Effective date: 20160905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20210112

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20210305

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160216

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220216

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240219

Year of fee payment: 19

Ref country code: GB

Payment date: 20240219

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240220

Year of fee payment: 19